Anti-Human CD30 Recombinant Antibody (Iratumumab)

Customer Review

There are currently no Customer reviews or questions for TAB-144. Click the button above to contact us or submit your feedback about this product.

Citations

1. Tosetti, Francesca, et al. "Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells." Oncoimmunology 7.5 (2018): e1421889. https://doi.org/10.1080/2162402x.2017.1421889
   This study investigates the role of ADAM10 (A Disintegrin And Metalloprotease 10) inhibitors in preventing sheddase activity in Hodgkin lymphoma (HL) and stromal cells. The research demonstrates that the mature bioactive form of ADAM10 is released in exosome-like vesicles (ExoV) by both HL cells and lymph node mesenchymal stromal cells. Notably, the researchers found that specific ADAM10 inhibitors (LT4 and CAM29) can localize in the endolysosomal compartment, be released in ExoV, and subsequently be endocytosed by bystander cells. These inhibitors effectively prevent ADAM10 sheddase activity carried by ExoV, which otherwise facilitates the release of cytokines like TNFα (a lymphoma growth factor) and soluble molecules such as sMICA or sCD30 that potentially interfere with host immune surveillance or immunotherapy.
   Creative Biolabs provided the anti-CD30 human antibody Iratumumab for this research, which was essential for studying antibody-dependent cellular cytotoxicity (ADCC) against HL cells. The antibody enabled researchers to demonstrate that ADAM10 inhibitors can reduce CD30 shedding and maintain the biological effects of both the antibody-drug conjugate Brentuximab-Vedotin and Iratumumab on HL cells. This contribution was significant as it helped establish that ADAM10 blockers can interfere with the immune escape process in the lymphoma microenvironment, potentially allowing for the development of effective anti-lymphoma immune responses and efficient antibody-based immunotherapies.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-144, RRID: AB_3111832)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Iratumumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Iratumumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "Iratumumab"

Afuco™ Anti-TNFRSF8 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-144)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD30. It is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.

DrugMonitor™ Anti-Iratumumab Antibody (VS-1224-YC615)

Iratumumab is a human monoclonal antibody used for treating relapsed refractory CD30-positive lymphoma and other oncological diseases. The DrugMonitor™ Anti-Iratumumab Antibody (VS-1224-YC615) is an anti-drug antibody (ADA) against Iratumumab. This drug-based antibody is raised in mice immunized with the Iratumumab. The anti-Iratumumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Iratumumab in samples.

See other products for "TNFRSF8"

Select a product category from the dropdown menu below to view related products.